Trial | Interventions (number of participants analysed) | Timepoints | Scales | Notes |
---|---|---|---|---|
Cloutier 2013 [24] | Oxycodone/naloxone (83) Placebo (83) | 4Â weeks | 0 to 100 VAS 5-point scale a | Crossover design. Analysed like parallel design with 83 participants in each group |
Dreiser 2003 [25] | Diclofenac (124) Ibuprofen (122) Placebo (123) | Baseline | 0 to 100 VAS 4-point scale b | Â |
Eken 2004 | Acetaminophen (46) Morphine (45) Dexketoprofen (46) | Baseline 15Â min 30Â min | 0 to 100 VAS 4-point scale a | Data converted from median (range) |
Friedman 2006 [27] | Methylprednisolone (39) Placebo (43) | Baseline 1Â week 3Â months | 0 to 10 NRS 4-point scale b | Individual patient data provided |
Friedman 2015 [3] | Cyclobenzaprine (103) Oxycodone/acetaminophen (104) Placebo (104) | 1Â week 3Â months | 0 to 10 NRS 4-point scale b | Individual patient data provided |
Goforth 2014 [28] | Eszopiclone (32) Placebo (20) | Baseline 1Â week 2Â weeks 4Â weeks | 0 to 100 VAS 5-point scale a | Â |
Gordon 2010a [29] | Buprenorphine (78) Placebo (78) | 4Â weeks | 0 to 100 VAS 5-point scale a | Crossover design. Analysed like parallel design with 78 participants in each group based on ITT analysis |
Gordon 2010b [30] | Buprenorphine (79) Placebo (79) | 4Â weeks | 0 to 100 VAS 5-point scale a | Crossover design. Analysed like parallel design with 79 participants in each group based on ITT analysis |
Innes 1998 [31] | Ketorolac (62) Acetaminophen (60) | Baseline | 0 to 100 VAS 5-point scale b | Â |
Lasko 2012 [32] | Tramadol (141) Placebo (136) | Baseline | 0 to 10 NRS 4-point scale a | Â |
O’Donnell 2009 [34] | Celecoxib (396) Tramadol (396) | 6 weeks | 0 to 10 NRS c 0 to 100 VAS | Data presented as change from baseline |
Thurel 1991 [33] | Codeine (25) Dextropropoxyphene (25) | Baseline | 0 to 100 VAS 5-point scale b | Â |